• Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

    5 days ago - By San Diego Biotechnology

    ST. LOUIS & SAN DIEGO--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented preclinical data on WU-NK-101,...
    Read more ...